Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan

Pediatric Transplantation

Volumn 10, Issue 5, 2006, Pages 635-638

  Ijichi, Osamu ^a   Ishikawa, Shuji ^a   Shinkoda, Yuichi ^a   Tanabe, Takayuki ^a   Okamoto, Yasuhiro ^a   Takamatsu, Hideo ^a   Inomata, Yukihiro ^b   Kawano, Yoshifumi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Congestive heart failure; Hepatoblastoma; Irinotecan; Liver transplantation

Indexed keywords

ALPHA FETOPROTEIN; ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; DOXORUBICIN; IRINOTECAN;

ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE TIME EFFECT RELATION; HEART FAILURE; HEPATOBLASTOMA; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; LUNG METASTASIS; MALE; NAUSEA; NEUTROPENIA; PRESCHOOL CHILD; RELAPSE; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 33745727139     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00517.x     Document Type: Article

References (14)

1. VON SCHWEINITZ D, BYRD DJ, HECKER H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Eur J Cancer 1997: 33: 1243-1249.
2. CARCELLER A, BLANCHARD H, CHAMPAGNE J, ST-VIL D, BENSOUSSAN AL. Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma. J Pediatr Surg 2001: 36: 755-759.
3. RANEY B. Hepatoblastoma in children: A review. J Pediatr Hematol Oncol 1997: 19: 418-422.
4. OTTE JB, PRITCHARD J, ARONSON DC, et al. Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004: 42: 74-83.
5. BLANEY S, BERG SL, PRATT C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 2001: 7: 32-37.
6. PALMER RD, WILLIAMS DM. Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 2003: 41: 78-80.
7. PRITCHARD J, BROWN J, SHAFFORD E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000: 18: 3819-3828.
8. TIAO GM, BOBEY N, ALLEN S, et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005: 146: 204-211.
9. BOMGAARS L, KERR J, BERG S, et al. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 2006: 46: 50-55.
10. KUSHNER BH, KRAMER K, MODAK S, et al. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer 2005: 20: 858-862.
11. MUGISHIMA H, MATSUNAGA T, KEIKO Y, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 2002: 24: 94-100.
12. GAJJAR A, CHINTAGMPALA MM, BOWERS DC, et al. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 2002: 97 (Suppl.): 2374-2380.
13. SUGIYAMA K, OMACHI K, FUJIWARA K, et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma. Cancer 2002: 94: 594-600.
14. HOUGHTON P, CHESHIRE P, HALLMAN J, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995: 36: 393-403.